Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia

Binghe Xu; Sung Bae Kim; Kenichi Inoue; Jurueyjiuan Lee; Bo Zhang; Richard Bryce; Louis W.C. Chow

doi:10.2217/fon-2019-0222

Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia

Binghe Xu
, Sung Bae Kim
, Kenichi Inoue
, Jurueyjiuan Lee
, Bo Zhang
, Richard Bryce
, Louis W.C. Chow

Health Science Center

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Aim: To evaluate the safety and efficacy of neratinib-based therapy in Asian patients with HER2-positive metastatic breast cancer (MBC). Patients & methods: We performed a pooled analysis of seven early-phase studies of neratinib given either as monotherapy or in combination with chemotherapeutic agents or trastuzumab in patients with advanced solid tumors. Results: A total of 793 patients with HER2-positive MBC were included in the efficacy analysis (Asia: 271 patients; other regions: 522 patients). The overall response rate in patients from Asia was 66.4% (180/271) and the median progression-free survival was 55.6 weeks. The most common adverse event in patients from Asia was diarrhea (all-grade: 96.3%; grade 3: 27.4%). Conclusion: Neratinib-based therapy is safe and effective in patients with HER2-positive MBC from Asia.

Original language	English
Pages (from-to)	3243-3253
Number of pages	11
Journal	Future Oncology
Volume	15
Issue number	28
DOIs	https://doi.org/10.2217/fon-2019-0222
State	Published - 2019

Keywords

Asia
efficacy
HER2
metastatic breast cancer
neratinib
pooled analysis
safety
tyrosine kinase inhibitor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2019-0222

Cite this

@article{59431890d65e42dc9567c2aa283a21a7,

title = "Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia",

abstract = "Aim: To evaluate the safety and efficacy of neratinib-based therapy in Asian patients with HER2-positive metastatic breast cancer (MBC). Patients \& methods: We performed a pooled analysis of seven early-phase studies of neratinib given either as monotherapy or in combination with chemotherapeutic agents or trastuzumab in patients with advanced solid tumors. Results: A total of 793 patients with HER2-positive MBC were included in the efficacy analysis (Asia: 271 patients; other regions: 522 patients). The overall response rate in patients from Asia was 66.4\% (180/271) and the median progression-free survival was 55.6 weeks. The most common adverse event in patients from Asia was diarrhea (all-grade: 96.3\%; grade 3: 27.4\%). Conclusion: Neratinib-based therapy is safe and effective in patients with HER2-positive MBC from Asia.",

keywords = "Asia, efficacy, HER2, metastatic breast cancer, neratinib, pooled analysis, safety, tyrosine kinase inhibitor",

author = "Binghe Xu and Kim, \{Sung Bae\} and Kenichi Inoue and Jurueyjiuan Lee and Bo Zhang and Richard Bryce and Chow, \{Louis W.C.\}",

note = "Publisher Copyright: {\textcopyright} 2019 {\textcopyright} 2019 Professor Binghe Xu and coauthors.",

year = "2019",

doi = "10.2217/fon-2019-0222",

language = "英语",

volume = "15",

pages = "3243--3253",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "28",

}

TY - JOUR

T1 - Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia

AU - Xu, Binghe

AU - Kim, Sung Bae

AU - Inoue, Kenichi

AU - Lee, Jurueyjiuan

AU - Zhang, Bo

AU - Bryce, Richard

AU - Chow, Louis W.C.

PY - 2019

Y1 - 2019

N2 - Aim: To evaluate the safety and efficacy of neratinib-based therapy in Asian patients with HER2-positive metastatic breast cancer (MBC). Patients & methods: We performed a pooled analysis of seven early-phase studies of neratinib given either as monotherapy or in combination with chemotherapeutic agents or trastuzumab in patients with advanced solid tumors. Results: A total of 793 patients with HER2-positive MBC were included in the efficacy analysis (Asia: 271 patients; other regions: 522 patients). The overall response rate in patients from Asia was 66.4% (180/271) and the median progression-free survival was 55.6 weeks. The most common adverse event in patients from Asia was diarrhea (all-grade: 96.3%; grade 3: 27.4%). Conclusion: Neratinib-based therapy is safe and effective in patients with HER2-positive MBC from Asia.

AB - Aim: To evaluate the safety and efficacy of neratinib-based therapy in Asian patients with HER2-positive metastatic breast cancer (MBC). Patients & methods: We performed a pooled analysis of seven early-phase studies of neratinib given either as monotherapy or in combination with chemotherapeutic agents or trastuzumab in patients with advanced solid tumors. Results: A total of 793 patients with HER2-positive MBC were included in the efficacy analysis (Asia: 271 patients; other regions: 522 patients). The overall response rate in patients from Asia was 66.4% (180/271) and the median progression-free survival was 55.6 weeks. The most common adverse event in patients from Asia was diarrhea (all-grade: 96.3%; grade 3: 27.4%). Conclusion: Neratinib-based therapy is safe and effective in patients with HER2-positive MBC from Asia.

KW - Asia

KW - efficacy

KW - HER2

KW - metastatic breast cancer

KW - neratinib

KW - pooled analysis

KW - safety

KW - tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/85073667695

U2 - 10.2217/fon-2019-0222

DO - 10.2217/fon-2019-0222

M3 - 文章

C2 - 31432689

AN - SCOPUS:85073667695

SN - 1479-6694

VL - 15

SP - 3243

EP - 3253

JO - Future Oncology

JF - Future Oncology

IS - 28

ER -

Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this